This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
UMN Pharma, Inc.
Drug Names(s): norovirus VLP + rotavirus VP6, UMN Noro/Rotavirus Vaccine, UMN-2003/2002
Description: The vaccine candidate is a norovirus VLP + rotavirus VP6 non live injectable adjuvant-freevaccine for the prevention of two major causative agents of acute gastroenteritis in one shot.
The norovirus VLP + rotavirus VP6 combination vaccine has been shown to be highly immunogenic inmice and potentiates the immune response ofeach component. The immune response is targeted against different viral strains of norovirusand rotavirus and is long lasting. Therefore, researchers believe the vaccine should induce cross-protective longlasting immunity against the two enteric viruses.
Deal Structure: The noro/rotavirus vaccine was licensed by UMN from the University of Tampere Vaccine Research Center.
Pink Sheet Diagnostic Tests
Additional information available to subscribers only: